Merck's oral PCSK9 inhibitor shows 55.8% LDL-C reduction in trial

Merck's oral PCSK9 inhibitor shows 55.8% LDL-C reduction in trial
#Merck039s #oral #PCSK9 #inhibitor #shows #LDLC #reduction #trial